|
|
发表于 22-6-2009 06:47 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 22-6-2009 06:48 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 22-6-2009 06:50 PM
|
显示全部楼层
分享： http://americanbulls.com/StockPa ... cker=NASD&TYP=S
CELL THERAPEUTICS INC CDT-COM
Daily Commentary
WAIT - Candlestick Analysis
Today’s Candlestick Patterns: White Candlestick
Our system posted a WAIT today. The previous SELL recommendation was issued on 06.11.2009 (8) days ago, when the stock price was 1.5600. Since then CTIC has fallen -2.56% .
Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays. |
|
|
|
|
|
|
|
|
|
|
|
发表于 22-6-2009 06:57 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 22-6-2009 07:05 PM
|
显示全部楼层
原帖由 jochen 于 22-6-2009 06:57 PM 发表 
你是女生。。。当然把你摆上神台。。。。
ctic milan 听说 开始 涨。。。
结果 halted 一阵子。。。
涨了 10%。。
希望再接再厲。
那么等下US-Market的CTIC也不甘落于後了。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 22-6-2009 07:10 PM
|
显示全部楼层
分享：
StandoutStocks.com: "Stocks that Standout" picks for today are: AIRV, CTIC, EFUT, FLEX - Mon. June 22, 2009; Posted: 04:41 AM
Jun 22, 2009 (M2 PRESSWIRE via COMTEX) -- FLEX | Quote | Chart | News | PowerRating -- "Stocks that Standout" picks for today are: Airvana, Inc. (NASDAQ: AIRV), Cell Therapeutics, Inc. (Nasdaq: CTIC), eFuture Information Technology Inc. (NASDAQ: EFUT), Flextronics International Ltd. (NASDAQ: FLEX)!
http://www.tradingmarkets.com/.site/news/Stock%20News/2381994/ |
|
|
|
|
|
|
|
|
|
|
|
发表于 23-6-2009 03:16 AM
|
显示全部楼层
|
今天调整。。CTIC的波动不大。。1.48。。还有谁在加码吗？。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 23-6-2009 08:57 AM
|
显示全部楼层
原帖由 木嘴 于 23-6-2009 03:16 AM 发表
今天调整。。CTIC的波动不大。。1.48。。还有谁在加码吗？。。
1.47 Contra x 5粒 （T+5）。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 23-6-2009 09:20 AM
|
显示全部楼层
還是卡 ....... |
|
|
|
|
|
|
|
|
|
|
|
发表于 23-6-2009 11:05 AM
|
显示全部楼层
回复 73# 葉芬 的帖子
全部都是医药股哦  |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 12:01 AM
|
显示全部楼层
|
卡帖 。。。。。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 12:53 AM
|
显示全部楼层
原帖由 葉芬 于 23-6-2009 08:57 AM 发表 
1.47 Contra x 5粒 （T+5）。
wahh....T+5.....那么好。。。。
CONTRA 肯定不用担心，，，，， |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 12:56 AM
|
显示全部楼层
原帖由 木嘴 于 23-6-2009 03:16 AM 发表
今天调整。。CTIC的波动不大。。1.48。。还有谁在加码吗？。。
这两天的大盘 全部下到。。。。。恐怖。。
我之前 1。27 和 1。39 进的 都卖了。。。。
希望 下多一点。。。。。结束前， 或明天（开市）收多一点，，
这两天。。。买大股 的都见红！
Citigroup.....MGM....LVS.....
hallelujah.... |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 12:58 AM
|
显示全部楼层
原帖由 葉芬 于 23-6-2009 10:20 AM 发表
目前手上的美國股票有：
a) CTIC - 68%
b) HEB - 12%
c) GNBT - 20%
叶姐姐的 HEB 脱手了？？
看到 今天。。。。。可怕。。。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 12:59 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 01:01 AM
|
显示全部楼层
这新帖 真 tmd 卡。。。。。
回复都 “bek chek“，。。。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 01:02 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 02:56 AM
|
显示全部楼层
目前手上的美國股票有：
a) CTIC - 31%
b) HEB - 49%
c) GNBT - 20% |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 05:40 PM
|
显示全部楼层
好消息：
http://news.prnewswire.com/ViewC ... 05049282&EDATE=
Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Completed NDA submission could lead to marketing approval in Q4-2009
SEATTLE, June 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.
"This is a major milestone for CTI and is the cornerstone of a turnaround strategy for us in meeting our goals of becoming a profitable operating business," said James A. Bianco, M.D., Chief Executive Officer of CTI. "With more than 76,000 pages and 500,000 hyperlinks this submission represents the hard work of many CTI employees dedicated to making a difference in the lives of patients with cancer. This also represents a significant advance in the treatment of patients with relapsed/refractory aggressive NHL, a patient population which the FDA has acknowledged represents an unmet medical need."
About the PIX 301 EXTEND Trial
CTI's EXTEND (PIX 301) clinical trial (the "PIX 301 EXTEND trial") was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population as selected by the physician.
CTI previously announced that its pivotal PIX 301 EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14 out of 70 patients (20.0%) for the pixantrone arm compared to four out of 70 patients (5.7%) for the standard chemotherapy arm, p=0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to eight out of 70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (ORR) (26 out of 70 (37.1%) for the pixantrone arm compared to ten out of 70 (14.3%) for the control arm, p=0.003). Additionally, pixantrone experienced a statistically significant improvement in median progression-free survival (PFS), compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p=0.007, respectively). PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.
The most common grade 3/4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3/4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3/4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3/4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. |
|
|
|
|
|
|
|
|
|
|
|
发表于 24-6-2009 05:43 PM
|
显示全部楼层
轉帖：分享
http://finance.google.com/group/ ... ad/44a34a4e41cf7839
~~♪ REUTERS: NDA FILING is DONE! ... Now wait Q4 (Record is 3,5 mths)~~
http://www.stupidvideos.com/video/animals/Salsa_Dog_1/#237627
~~~~~~~~~~~~~~~~~~~~~~~~
Pixantrone is currently available in Europe on a named-patient basis.
It takes Max. 45 days to GRANT the Priority Review.. (We expect a yes).
3-5$
IMO 85-95 % Pix ...IF granted PR we will have an Approval in Q4 = $10+
{Record is 3,5 Mths from the PR Granted date}
IMHO ... From End of July count ... = or > 3,5 mths ...
... From Mid - November to end of Dec (Q4) : i expect an APPROVAL
~~~~~~~~~~~~~
ALL THIS... WITHOUT ... THE OPAXIO NEWS
OPAXIO in JULY / August in EUROPE: (Waiting anytime the HIGHLY
expected Approval!)
Marketing Authorization Application (MAA) to the European Medicines
Agency (EMEA)
Another 10+ $ a minimum ... there also ...
NO ... WE DONT DO THINGS HALF WAY ...
IF some drug companies like DNDN went 26$ BEFORE its approval ... my
estimates are then a MINIMUM ...and remember we've got two drugs (a
third one Brostallicin in P II)
Read my "lips" .... T ___ W ___O ... drugs to be approved ...
Sorry Ladies lol ...for some guys to "wake up" here: How are you going
to explain to your Mother-In-law at Christmas that you knew all about
it ... but didn't do anything ... hum?
Psst ... Stay away from her heavy frying pan if she holds one in her
hand ... lol
pps
~~♪ REUTERS: NDA FILING is DONE! ... Now wait Q4 (Record is 3,5 mths)~~ |
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2015 
51
